Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 1998

View Archived Issues

Proteus: preliminary year-end 1998 highlights

Biora enters academic partnership for Emdogain development

Thalidomide treatment of chronic ulceration in AIDS patients

Inhibition of HIV-1 replication through stem cell gene therapy: results from phase I studies

SP-303: new treatment for AIDS-associated diarrhea

Positive preliminary results reported for extended-use clinical trial of RenaGel

Quality of life improves in advanced HIV-infected patients treated with DHEA

Oxandrolone treatment results in robust anabolic effect in HIV-infected patients

COX-2 inhibitors for GBS and CIDP

Spartaject busulfan enters phase I for pediatric BMT patients

Boston Life Sciences submits further data supporting Therafectin NDA

Trimeris begins phase II trial of T-20 in HIV patients

New AIDS drugs in development at Triangle

Zeria discloses new thromboxane antagonists for thrombosis

Anti-H. pylori compounds prepared at Fujisawa

Benzamide derivatives in development at Kyorin for diabetes

ACAT inhibitors claimed by Sanwa for hyperlipidemia/atherosclerosis

Taisho claims antipsychotic agents devoid of extrapyramidal side effects

Analgesics prepared at Ostuka

P&U characterizes dual inhibitor of both 5alpha-reductase isozymes

FDA advisory committee to review Pletal NDA next week

Approvable letter issued for Xopenex

Astra and Merck & Co. complete restructuring ageement

Novel ACAT inhibitor from Nihon Nohyaku for hyperlipidemia and atherosclerosis

BO-653: an antioxidant with potential in restenosis

Further data support development of TAS-301 for restenosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...